Trial Profile
The DUTRENEO Trial: A Prospective Study to Individualize the Approach With DUrvalumab (MEDI4736) and TREmelimumab in NEOadjuvant Bladder Cancer Patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Apr 2023
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary) ; Cisplatin; Doxorubicin; Gemcitabine; Methotrexate; Paclitaxel; Vinblastine
- Indications Bladder cancer; Ureteral neoplasms; Urethral cancer; Urogenital cancer
- Focus Therapeutic Use
- Acronyms DUTRENEO
- 12 Apr 2023 Status changed from active, no longer recruiting to completed.
- 13 Feb 2023 Planned End Date changed from 1 Dec 2022 to 30 Apr 2023.
- 20 Sep 2022 Planned primary completion date changed from 1 Jul 2022 to 1 Dec 2022.